Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sibutramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 15/20 | 0.81 |
| ▸ | SLC6A4 known ✓ | P31645 | 14/20 | 0.81 |
| ▸ | SLC6A2 known ✓ | P23975 | 7/20 | 0.81 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.81 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.81 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.81 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.81 |
| ▸ | HTR2A | P28223 | 1/20 | 0.81 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.81 |
| ▸ | HTR2B | P41595 | 1/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.79 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.79 |
| ▸ | TSHR | P16473 | 2/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | MAPT | P10636 | 1/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.79 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sibutramine SCHEMBL4804258 | 0.93 | SLC6A3 (0.85) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL16312 | 0.90 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL2672138 | 0.90 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL3707643 | 0.90 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL2955 | 0.90 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL3715426 | 0.89 | SLC6A3 (0.79) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL3705071 | 0.89 | SLC6A3 (0.79) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL3707037 | 0.89 | SLC6A3 (0.79) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL4880870 | 0.89 | SLC6A3 (0.82) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL7191483 | 0.88 | CYP3A4 (1.00) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393977-B2 | Dicarboxylic acid salt of sibutramine | CJ CHEILJEDANG CORPORATION (KR) | 2008-07-01 | — | — | US | claimed |
| US-20070191482-A1 | Dicarboxylic acid salt of sibutramine | CJ CORPORATION (KR) | 2007-08-16 | — | — | US | claimed |
| WO-2006073290-A1 | A DICARBOXYLIC ACID SALT OF SIBUTRAMINE | CJ CORPORATION (KR) | 2006-07-13 | — | — | WO | claimed |
| US-7393977-B2 | Dicarboxylic acid salt of sibutramine | CJ CHEILJEDANG CORPORATION (KR) | 2008-07-01 | — | — | US | disclosed |
| US-20070191482-A1 | Dicarboxylic acid salt of sibutramine | CJ CORPORATION (KR) | 2007-08-16 | — | — | US | disclosed |
| WO-2006073290-A1 | A DICARBOXYLIC ACID SALT OF SIBUTRAMINE | CJ CORPORATION (KR) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191482-A1 | Dicarboxylic acid salt of sibutramine | SLC5A1, GPR119, SLC5A2 | SLC6A3 7/4885SLC6A4 13/4885SLC6A2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.